Physician profile
Daniel Errampalli
NPI 1689662975
$17,331.39
in general payments reported to CMS, 2019-2025
47 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,291 · 2020: $562 · 2021: $1,282 · 2022: $3,160 · 2023: $3,612 · 2024: $3,207 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,832 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,832.12 |
| Education | $204.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,165.15 | 2019-2025 | |
| Janssen Biotech, INC. | $2,731.07 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,969.18 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $991.48 | 2019-2025 | Trulance, Xifaxan |
| Celgene Corporation | $739.51 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $663.33 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $552.91 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $506.22 | 2019-2025 | |
| Ardelyx, INC. | $482.84 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $467.13 | 2020-2025 | |
| Genzyme Corporation | $366.39 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $358.00 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $320.17 | 2023-2025 | Voquezna |
| Vivus LLC | $277.39 | 2020-2025 | Pancreaze |
| Lilly USA, LLC | $237.67 | 2024-2025 | Omvoh |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Errampalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.